


2/2


***Histogram: Kt/V Distribution count for 3 months***  
1 monthly measurement per patient



FRANCE 1301


**Fig. 1**

***Histogram: Kt/V Distribution count for 3 months***  
1 monthly measurement per patient



**Fig. 2**


*Histogram: Kt/V Distribution count for 3 months*  
1 monthly measurement per patient



**Fig. 3**

# *Histogram: Kt/V Distribution count for 3 months*


1 monthly measurement per patient



SPAIN 1503

**Fig. 4**

*Histogram: Kt/V Distribution count for 3 months*  
1 monthly measurement per patient



HUNGARY 1403

**Fig. 5**

## Overall Clinic SD

“Defines the ability of the clinic to deliver RxS within the specs”






Fig. 6

**Inter Patient Variation**  
12 Pts With BW Between 60-70 Kg




**Fig. 7**

**Intra Patient Variation**  
6 Patients, 4 monthly consecutive Treatments



**Fig. 8**





Process Statistics

Capacity Indices	Act. % Outside SL	82.5%
Cp <sup>a</sup>		4.737
CpU <sup>a</sup>		-4.740
CpK <sup>a</sup>		-4.740

The normal distribution is assumed. LSL = 1.2 and USL = 1.4.

a. The estimated capability sigma is based on the mean of the sample moving ranges.

Fig. 9





Fig. 10




Process Statistics

Act. % Outside SL	59.5%
CP <sub>a</sub>	.163
CP <sub>U<sup>a</sup></sub>	.007
CP <sub>L<sup>a</sup></sub>	.007

The normal distribution is assumed. LSL = 1.2 and USL = 1.4.  
 a. The estimated capability sigma is based on the mean of the sample moving ranges.

**Fig. 11**

FOSTF "022360




Process Statistics

Capability Indices	Act. % Outside SL
C <sub>pa</sub>	79.3%
C <sub>pu</sub>	.320
C <sub>pk</sub>	-.057

The normal distribution is assumed. LSL = 1.2 and USL = 1.4.  
a. The estimated capability sigma is based on the mean of the sample moving ranges.

Fig. 12

Kt/V USA (1 Month average all clinics)



Process Statistics

Capability Indices	Act. % Outside SL	90.8%
CPa		.354
CpUa		-.405
CpKa		-.405

The normal distribution is assumed. LSL = 1.2 and USL = 1.4.  
a. The estimated capability sigma is based on the mean of the sample moving ranges.

Fig. 13

Percent of Treatments  
- Above or Below the Specs ("Defects") -  
per clinic per country




Fig. 14





Fig. 15



**Fig. 16**








Fig. 17



**Fig. 18**

### Spain (10 Clinics)



**Fig. 19**





Fig. 20



**Fig. 21**




Fig. 22






Fig. 23




**Fig. 24**






**Fig. 25**



**Fig. 26**

# USA Clinics (Reimbursement \$200-205 per Rx)



**Fig. 27**




Fig. 28

# Total Process Time Longest/Shortest/Median (No Reuse)





Fig. 29

# Treatment Step Time Longest/Shortest/Median

(N=119)



**Fig. 30**

## Disinfection Step Time

Longest/shortest/median

(N=119)




Fig. 31

## Process, Treatment and Other Steps Time Longest/Shortest/Median





Fig. 32



**Total Process Staff Time**  
**Longest/shortest/median**  
(No Reuse)



**Fig. 33**

# Staff Time Treatment Step Longest/shortest/median

(N=119)






Fig. 34

**Staff Time**  
**Total Process, Treatment and Other Steps Time**  
**Longest/Shortest**  
**(No Reuse)**




**Fig. 35**

**IMPROVEMENT POSSIBILITY**  
Current Median Staff Time/ "Ideal" Median/ the Median Difference



**Fig. 36**

**Reuse US (N=34)**  
**Total Process Time**  
Longest/Shortest/Median



**Fig. 37**

# Total Process Time Comparison No Reuse vs Reuse

Longest/Shortest/Median

(No Reuse)




Fig. 38

Reuse US  
Median staff time reuse/ without the reuse step/no reuse




Fig. 39

US clinics  
Median staff time reuse treatments without the reuse  
step/staff time no reuse treatments and the difference




Fig. 40



# Shortest Total Process Staff Times reuse/no reuse in US (all treatments)




Fig. 41




Fig. 42





Fig. 43



Histogram and Box and Whisker Plot of EBITDA per treatment

**Fig. 44**